Navigation Links
Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease
Date:4/26/2011

e intent to achieve increased distribution in targeted brain regions. Medtronic has developed a drug pump and specially designed catheter to enable precise delivery of the GDNF variant into a targeted area of the brain consistently over time. This combination of a novel GDNF variant, paired with an optimized delivery system, has the potential to impact the neurodegeneration that leads to worsening symptoms and progression of Parkinson's disease.  

"Our collaboration with Lilly is bringing together the expertise of both companies to develop a new approach to the treatment of Parkinson's disease," said Steve Oesterle, M.D., senior vice president of Medicine and Technology at Medtronic.  "One of the most significant challenges in delivering a biologic treatment for neurodegenerative diseases is crossing the blood brain barrier.  We have extensive experience in targeted drug delivery and technology that allow delivery of therapeutic agents directly to the brain."

"While a potential treatment approach resulting from this research is many years away, we are heartened by Lilly and Medtronic's commitment to develop a neurotrophic-based therapy for Parkinson's disease," said Katie Hood, CEO of The Michael J. Fox Foundation for Parkinson's Research. "Our foundation has funded separate, ongoing work in neurotrophic factors for years, and we continue to believe in their promise to lead to a critically needed disease-modifying treatment for Parkinson's."

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at '/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... , April 28, 2015 The ... around $3,876.3 million by 2019, growing at a CAGR ... through the TOC of the pharmacy information systems market, ... This also provides a glimpse of the segmentation of ... is supported by various tables and figures. ...
(Date:4/28/2015)... , April 28, 2015  Olympus, a precision technology ... and surgical procedures, among other core businesses, announced today ... Brooklyn Park, MN. The new ... designed to position the company for continued long-term growth ... dedication ceremony took place on April 27 and was ...
(Date:4/28/2015)... 28, 2015 Oramed Pharmaceuticals Inc. (NASDAQ: ... Shareholders and Associates, I am very excited to ... much-awaited Phase IIb clinical trial for oral insulin (ORMD-0801) and ... commence the trial in the coming weeks. This clinical trial will ... marks a significant milestone for the company, literally putting us ...
Breaking Medicine Technology:Pharmacy Information Systems Market is Expected to Reach $3,876.3 Million by 2019, at a CAGR of 7.7% From 2014 to 2019 2Pharmacy Information Systems Market is Expected to Reach $3,876.3 Million by 2019, at a CAGR of 7.7% From 2014 to 2019 3Olympus Opens New Surgical Innovation Center, Positioning Company for Long-term Growth 2Olympus Opens New Surgical Innovation Center, Positioning Company for Long-term Growth 3Olympus Opens New Surgical Innovation Center, Positioning Company for Long-term Growth 4Oramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter 2Oramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter 3
... Colo., June 21, 2011 Medivance® Inc . ... the Ernst & Young Entrepreneur Of The Year ® ... & Life Sciences category. According to Ernst & Young ... and extraordinary success in such areas as innovation, financial ...
... a leader in global healthcare primary market research and influence ... 50 market research firms in the United States. ... to be part of the Honomichl 50, and a testament ... panel of physicians and allied health professionals, and innovative technology. ...
Cached Medicine Technology:Robert Kline, President & CEO, Medivance Named Ernst & Young Entrepreneur Of The Year® 2011 Regional Award Winner 2Robert Kline, President & CEO, Medivance Named Ernst & Young Entrepreneur Of The Year® 2011 Regional Award Winner 3AlphaDetail, Healthcare Market Research Specialist, Named to the Honomichl Top 50 2
(Date:4/28/2015)... PA (PRWEB) April 28, 2015 Helping ... decision-making process when a loved one dies can be ... the funeral arrangements and final tribute can ... families in need, Beinhauer Family Funeral Homes ... services offered to families by doubling its number of ...
(Date:4/28/2015)... 28, 2015 Two leaders in patient ... to Becker's Hospital Review’s list of 50 Experts ... Pronovost, M.D., Ph.D. , director of the Armstrong ... vice president for patient safety and quality at Johns ... vice president of medical affairs and chief patient safety ...
(Date:4/28/2015)... Georgia State University’s School of Public ... will partner with the school on efforts to improve ... that produces more tobacco and has more smokers than ... Tobacco Control Partnership-Tobacco Free Cities, will focus on a ... support tobacco control efforts and where public health organizations ...
(Date:4/28/2015)... 2015 Vancouver personal injury lawyers at ... it is smarter to call an attorney before calling ... The blog reasons that there are several benefits of ... well-versed with the law and can help clients reach ... to on their own. Competent and experienced personal injury ...
(Date:4/28/2015)... 28, 2015 The biologics safety testing ... drivers for the market include growth of the pharmaceutical ... drug launches. Over the years, the number of drug ... and 2010, the FDA approved 225 drug applications and ... Europe accounted for 3,822 of the pharmaceutical and 1,998 ...
Breaking Medicine News(10 mins):Health News:Beinhauer's Increasing Number of Celebrants to Meet Growing Demand for Personalized Funeral Ceremonies 2Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 2Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 3Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 4Health News:Georgia State Names Partner Cities For Tobacco Control Project 2Health News:Vancouver Personal Injury Lawyers Recently Stated in Latest Blog That It Is Smarter To Call A Lawyer Before ICBC 2Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 2Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 3Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 4
... STAMFORD, Conn., Aug. 27 American children miss more ... other two diseases combined.(1) As parents help their kids prepare for ... a lifetime of good oral health with the new Philips Sonicare ... Sonicare For Kids is specially designed to support kids, needs at ...
... , DES PLAINES, Ill. and NEW ... into an agreement with Pfizer Inc to develop a molecular diagnostic ... the presence of gene rearrangements. Pfizer has developed a novel ... of many cancers. To be eligible to receive Pfizer,s oral ...
... those with deceased donor transplant organs, study shows , ... disease may do just as well receiving treatment at ... donor, new research has found. , Researchers in Canada ... had either received a kidney transplant from a deceased ...
... , , , ... and CHATTANOOGA, Tenn., Aug. 27 Sandata Technologies, Inc., a ... healthcare and social services communities, and Volunteer State Health Plan ... announced an agreement by which VSHP will use Sandata,s IntegriCare ...
... China, Aug. 27 /PRNewswire-Asia/ -- On August 10, 2009, Winner,Medical ... entered into a contract with a machine producer in China ... This new machineries will constitute the ... operated in the Company,s,subsidiary in Huanggang, and it is expected ...
... , , CUPERTINO, Calif., ... today reported that it has signed an exclusive long term ... Inc. (NYSE: KG ). This agreement stipulates the ... based on DURECT,s manufacturing cost plus a specified percentage mark-up, ...
Cached Medicine News:Health News:Keep Oral Health in Check This School Year With the New Philips Sonicare for Kids Power Toothbrush 2Health News:Keep Oral Health in Check This School Year With the New Philips Sonicare for Kids Power Toothbrush 3Health News:Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy 2Health News:Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy 3Health News:Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy 4Health News:Home Dialysis a Good Option for Kidney Disease Patients 2Health News:Sandata Selected by Volunteer State Health Plan to Manage TennCare Choices 2Health News:Winner Medical Purchased New Purcotton Production Line to Meet Increasing Demand 2Health News:Winner Medical Purchased New Purcotton Production Line to Meet Increasing Demand 3Health News:DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R) 2Health News:DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R) 3Health News:DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R) 4
... Stylish and comfortable eye protection Properly ... 90% of scatter radiation. Our high quality ... and comfort with minimized weight. Our lenses ... optics that meet all industry standards. Most ...
... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
... lenses and frames are designed with the safety ... lenses are Schott RS-520 (also called SF-6) leaded ... These lenses meet standards, as set for optical ... ,While our eyewear is protecting your eyes, ...
... and frames are designed with the safety and ... are Schott RS-520 (also called SF-6) leaded glass, ... lenses meet standards, as set for optical clarity, ... ,While our eyewear is protecting your eyes, it ...
Medicine Products: